Skip to main content Skip to main navigation menu Skip to site footer

Kadar interleukin-17 plasma berkorelasi positif dengan kadar imunoglobulin M (IgM) anti phenolic glycolipid-1 (PGL-1) pada narakontak serumah pasien kusta tipe multibasiler



Abstract

Introduction: Household contacts are the group most at risk of contracting subclinical leprosy, which acts as a transmission source. Immunoglobulin M (IgM) anti-Phenolic Glycolipid-1 (PGL-1) serological indicates the abundance of M. leprae in person and Interleukin-17 (IL-17) levels play an important role in preventing clinical leprosy. Thus, this study aims to determine the correlation of IL-17 to IgM-anti PGL-1 in household contacts of multibacillary type leprosy patients.

Methods: This study was an analytic observational study with a cross-sectional approach. The research was conducted from October to November 2022 at the Skin and Venereology Polyclinic and the Clinical Pathology Laboratory, Prof. Hospital. Dr. I.G.N.G. Ngoerah Denpasar. Samples were selected using a consecutive sampling technique. The total sample was divided into groups of contacts and non-contacts. Data were analyzed using SPSS 23. The bivariate analysis used was chi-square, man-withney. Then a correlation analysis was performed using the Spearman rho test. The significant p-value was <0.05.

Results: The total number of samples obtained was 72. The mean levels of IL-17 and anti-PGL-1 IgM levels in the contact group were 45.47 ± 20.57 pg/ml and 605.59 ± 2,94.30 u/ml, while in the non-contact group were 31.46 ± 19.25 pg/ml and 140.46 ± 93.42 u/ml. There was a significant difference in IL-17 and anti-PGL-1 IgM levels in the contact and non-contact groups (p<0.001). Correlation analysis showed a weak positive relationship (r=0.290, p=0.014) between IL-17 levels and anti-PGL-1 IgM levels.

Conclusion: The levels of anti-PGL-1 and IL-17 IgM in contacts were higher than in non-contacts, with a significant difference. There was a significant weak positive correlation between levels of IL-17 and anti-PGL-1 IgM.

 

Pendahuluan: Narakontak serumah merupakan kelompok paling berisiko terjangkitnya kusta subklinis yang berperan sebagai sumber penularan. Pemeriksaan serologis Imunoglobulin M (IgM) anti Phenolic Glycolipid-1 (PGL-1) dapat menjadi indikasi banyaknya M. leprae dalam tubuh narakontak dan kadar Interleukin-17 (IL-17) berperan penting mencegah terjadinya kusta klinis. Untuk itu penelitian ini bertujuan untukmengetahui korelasi IL-17 terhadap IgM-anti PGL-1 pada narakontak serumah pasien kusta tipe multibasiler.

Metode: Studi ini merupakan observasional analitik dengan pendekatan potong lintang. Penelitian dilaksanakan mulai bulan Oktober - November 2022 di Poliklinik Kulit dan Kelamin dan Laboratorium Patologi Klinik, RSUP Prof. Dr. I.G.N.G. Ngoerah Denpasar. Sampel dipilih menggunakan teknik consecutive sampling.  Total sampel di bagi menjadi kelompok narakontak dan bukan narakontak. Data di analisis menggunakan SPSS 23. Analisis bivariat yang digunakan adalah chi-square, man-withney. Selanjutnya dilakukan analisis korelasi menggunakan uji Spearman rho. Nilai p dikatakan signifikan jika <0.05.  

Hasil: Total sampel yang diperoleh adalah 72. Rerata kadar IL-17 dan kadar IgM anti PGL-1 pada kelompok narakontak yaitu 45,47 ± 20,57 pg/ml dan 605,59 ± 294,30 u/ml sementara pada kelompok bukan narakontak yaitu 31,46 ± 19,25 pg/ml dan 140,46 ± 93,42 u/ml. Terdapat perbedaan yang signifikan pada kadar IL-17 dan IgM anti PGL-1 pada kelompok narakontak dan bukan narakontak (p<0.001). Analisis korelasi menunjukkan hubungan positif lemah nilai (r=0,290, p=0,014) antara kadar IL-17 dengan kadar IgM anti PGL-1.

Kesimpulan: Kadar IgM anti PGL-1 dan IL-17 pada narakontak lebih tinggi dari bukan narakontak dengan perbedaan yang signifikan. Terdapat korelasi positif lemah yang signifikan antar kadar IL-17 dan IgM anti PGL-1.

Keywords: IgM anti PGL-1 IL-17 kusta narakontak

References

  1. de Carvalho FM, Rodrigues LS, Duppre NC, Alvim IMP, Ribeiro-Alves M, Pinheiro RO, et al. Interruption of persistent exposure to leprosy combined or not with recent BCG vaccination enhances the response to Mycobacterium leprae-specific antigens. PLoS Negl Trop Dis. 2017;11(5):1–16.
  2. Wardana M, Swastika M, Rusyanti LM. Subclinical leprosy detection in contact person of multibacillary leprosy patients Made Wardana , Made Swastika , Luh Mas Rusyati Dermatology and Genital Department , Faculty of Medicine , Udayana University , Bali – Indonesia ABSTRACT Background : Lepros. Indones Joournal Biomed Sci. 10(2):10–4.
  3. Sakdiah S, Salim EM, Halfy Z, Argentina F, Kurniati N, Rahadiyanto Y. Comparison of interleukin- 17 level in leprosy and non-leprosy patients at Dr . Muhammad Hoesin Palembang general hospital. 2019;17.
  4. Putri WE, Budiamal S, Christopher PM. Leprosy and Immune System : An Insight into the Innate Immune System. Indian J Leprae. 2021;93:391–403.
  5. WHO. Global Leprosy Update, 2020. Wkly Epidemiol Rec. 2020;34(94):389–412.
  6. Dinas Kesehatan Propinsi Bali. Profil Kesehatan Provinsi Balu Tahun 2018. :1–269.
  7. Anonim. Register of patients at the Dermatology and Venereology Polyclinic, Sanglah Central General Hospital, Denpasar. January 2018 - December 2021. Unpublished. 2021;(December):2021.
  8. Hungria EM, Bührer-Sékula S, Oliveira RM, Aderaldo LC, Pontes MAA, Cruz R, et al. Mycobacterium leprae-Specific Antibodies in Multibacillary Leprosy Patients Decrease During and After Treatment With Either the Regular 12 Doses Multidrug Therapy (MDT) or the Uniform 6 Doses MDT. Front Immunol. 2018;9:915. Available from: https://pubmed.ncbi.nlm.nih.gov/29867930
  9. Santos MB, de Oliveira DT, Cazzaniga RA, Varjão CS, Dos Santos PL, Santos MLB, et al. Distinct Roles of Th17 and Th1 Cells in Inflammatory Responses Associated with the Presentation of Paucibacillary Leprosy and Leprosy Reactions. Scand J Immunol. 2017;86(1):40–9.
  10. Isailovic N, Daigo K, Mantovani A, Selmi C. Interleukin-17 and innate immunity in infections and chronic inflammation. J Autoimmun. 2015;60:1–11.
  11. Rahadiyanto SSE mart salim; Z hafy; F argentina; N kurniati; Y. Comparison of interleukin- 17 level in leprosy and non-leprosy patients at Dr . Muhammad Hoesin Palembang general hospital. 2019;17.
  12. Sakdiah S, Salim E mart, Hafy Z, Argentina F, Kurniati N, Rahadiyanto Y. Comparison of interleukin- 17 level in leprosy and non-leprosy patients at Dr . Muhammad Hoesin Palembang general hospital. J Innov Appl Pharm Sci. 2019;4(4):1–9.
  13. Gunawan H, Annissa M, Dwiyana R, Avriyanti E, Suwarsa O. Increased expression of interleukin-17A in the lesional skin indicates increase of serum antibody anti-phenolic glycolipid-I in leprosy patients. Biomed Biotechnol Res J. 2017;1(2):147.
  14. Priyadarshini IAU, Suryawati N, Rusyati LM. Kadar IL-10 plasma berkorelasi positif dengan kadar IgM anti PGL-1 pada narakontak serumah pasien kusta tipe multibasiler. Intisari Sains Medis. 2022;13(1):243–50. Available from: http://isainsmedis.id/
  15. Elice Wijaya, Luh Made Mas Rusyati IGAAP. Suplementasi seng (Zn) menurunkan kadar IgM anti PGL-1 pada narakontak serumah pasien kusta tipe multibasiler. Intisari Sains Medis. 2021;12(E-ISSN: 2503-3638):P-ISSN 2089-9084.
  16. de Almeida-Neto FB, Assis Costa VM, Oliveira-Filho AF, de Souza Franco E, Tavares Julião de Lima E V, Barros de Lorena VM, et al. TH17 cells, interleukin-17 and interferon-γ in patients and households contacts of leprosy with multibacillary and paucibacillary forms before and after the start of chemotherapy treatment. J Eur Acad Dermatol Venereol. 2015;29(7):1354–61.
  17. Teixeira CSS, Pescarini JM, Alves FJO, Nery JS, Sanchez MN, Teles C, et al. Incidence of and Factors Associated with Leprosy among Household Contacts of Patients with Leprosy in Brazil. JAMA Dermatology. 2020;156(6):640–8.
  18. Tiwari A, Suryawanshi P, Raikwar A, Arif M, Richardus JH. Household expenditure on leprosy outpatient services in the Indian health system: A comparative study. PLoS Negl Trop Dis. 2018;12(1):e0006181. Available from: https://doi.org/10.1371/journal.pntd.0006181
  19. Geani S, Rahmadewi, Astindari, Prakoeswa CRS, Sawitri, Ervianti E, et al. Risk factors for disability in leprosy patients: a cross-sectional study. Bali Med J. 2022;11(1 SE-ORIGINAL ARTICLE):197–201. Available from: https://balimedicaljournal.org/index.php/bmj/article/view/3311
  20. Abdallah M, Emam H, Attia E, Hussein J, Mohamed N. Estimation of serum level of interleukin-17 and interleukin-4 in leprosy, towards more understanding of leprosy immunopathogenesis. Indian J Dermatol Venereol Leprol. 2013;79(6):772–6.
  21. Barreto JG, Guimarães L de S, Leão MRN, Ferreira DVG, de Araújo Lima RA, Salgado CG. Anti-PGL-I seroepidemiology in leprosy cases: Household contacts and school children from a hyperendemic municipality of the Brazilian Amazon. Lepr Rev. 2011;82(4):358–70.
  22. Spencer JS, Brennan PJ. The role of Mycobacterium leprae phenolic glycolipid I (PGL-I) in serodiagnosis and in the pathogenesis of leprosy. Lepr Rev. 2011;82(4):344–57.
  23. Leturiondo AL, Noronha AB, do Nascimento MOO, Ferreira C de O, Rodrigues F da C, Moraes MO, et al. Performance of serological tests PGL1 and NDO-LID in the diagnosis of leprosy in a reference Center in Brazil. BMC Infect Dis. 2019;19(1):1–6.
  24. Zhang DF, Li HL, Zheng Q, Bi R, Xu M, Wang D, et al. Mapping leprosy-associated coding variants of interleukin genes by targeted sequencing. Clin Genet. 2021;99(6):802–11.
  25. Prakoeswa FRS, Maharani F, Fitriah M, Nugraha J, Soebono H, Prasetyo B, et al. Comparison of IL-17 and FOXP3+ Levels in Maternal and Children Leprosy Patients in Endemic and Nonendemic Areas. Interdiscip Perspect Infect Dis. 2021;2021.
  26. Curtis MM, Way SS. Interleukin-17 in host defence against bacterial, mycobacterial and fungal pathogens. Immunology. 2009;126(2):177–85.
  27. Cortela DCB, Souza Junior ALD, Virmond MCL, Ignotti E. Inflammatory mediators of leprosy reactional episodes and dental infections: A systematic review. Mediators Inflamm. 2015;2015.
  28. Albanesi C, Scarponi C, Sebastiani S, Cavani A, Federici M, Sozzani S, et al. A cytokine‐to‐chemokine axis between T lymphocytes and keratinocytes can favor Th1 cell accumulation in chronic inflammatory skin diseases. J Leukoc Biol. 2001;70(4):617–23.
  29. Sengupta U. Recent Laboratory Advances in Diagnostics and Monitoring Response to Treatment in Leprosy. Indian Dermatol Online J. 2019;10(2):106–14. Available from: https://pubmed.ncbi.nlm.nih.gov/30984583
  30. Nasution K, Nadeak K, Lubis SR. Igm anti pgl-1 antibody level in patients with leprosy: A comparative study between ear lobes capillary and median cubital vein blood samples. Open Access Maced J Med Sci. 2018;6(8):1346–8.
  31. Listiawan M. Perbedaan Profil Sistem Imun Orang Sehat dan Penderita Kusta di Daerah Endemis. Univ Airlangga Press. 2021;

How to Cite

Indah Jayanthi, A. A. ., Mas Rusyati, L. M., Dwi Puspawati, N. M. ., Elis Indira, I. G. A. A. ., Darmaputra, I. G. N. ., & Dwi Karmila, I. G. A. A. . (2023). Kadar interleukin-17 plasma berkorelasi positif dengan kadar imunoglobulin M (IgM) anti phenolic glycolipid-1 (PGL-1) pada narakontak serumah pasien kusta tipe multibasiler. Intisari Sains Medis, 14(1), 445–451. https://doi.org/10.15562/ism.v14i1.1694
ACM ACS APA ABNT Chicago Harvard IEEE MLA Turabian Vancouver
Download Citation
Endnote/Zotero/Mendeley (RIS) BibTeX

HTML
0

Total
0

Share

Search Panel

Anak Agung Indah Jayanthi
Google Scholar
Pubmed
ISM Journal

Luh Made Mas Rusyati
Google Scholar
Pubmed
ISM Journal

Ni Made Dwi Puspawati
Google Scholar
Pubmed
ISM Journal

I Gusti Ayu Agung Elis Indira
Google Scholar
Pubmed
ISM Journal

I Gusti Nyoman Darmaputra
Google Scholar
Pubmed
ISM Journal

I Gusti Ayu Agung Dwi Karmila
Google Scholar
Pubmed
ISM Journal